621.55MMarket Cap-1583P/E (TTM)
9.569High8.760Low1.34MVolume9.450Open9.340Pre Close12.08MTurnover2.40%Turnover RatioLossP/E (Static)68.38MShares19.71052wk High-3.32P/B506.77MFloat Cap6.06552wk Low--Dividend TTM55.75MShs Float64.540Historical High--Div YieldTTM8.66%Amplitude5.840Historical Low9.045Avg Price1Lot Size
Phathom Pharmaceuticals Stock Forum
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
No comment yet